Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

pembrolizumab 66Cyclophosphamide 44Cisplatin 43Nivolumab 36Paclitaxel 32Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Doxorubicin 19Bevacizumab 19Magnetic Resonance Spectroscopy 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Radiosurgery 15Letrozole 15Ipilimumab 15Fluorouracil 15Blood Specimen Collection 15palbociclib 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14Surveys and Questionnaires 13Specimen Handling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Linezolid × 90 days × Clear all
NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡